Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Arashiramar Kazralmaran
Country: Norway
Language: English (Spanish)
Genre: Politics
Published (Last): 6 January 2016
Pages: 257
PDF File Size: 14.17 Mb
ePub File Size: 20.20 Mb
ISBN: 872-2-55895-464-1
Downloads: 58921
Price: Free* [*Free Regsitration Required]
Uploader: Bradal

Title of the trial for lay people, in easily understood, i. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. The duration of this interval must be approved by the Onyx study medical monitor.

Both Female Only Male Only. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.

For these items you should use the filters and not add them to your search terms in the text field. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.


Clinical trials

Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Karnofsky or Lansky scores? For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.

Date on which this record was first entered in l-asparagniasa EudraCT database:. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Review by the Competent Authority or Ethics Committee in the country concerned. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? Age 18 years or younger at the time of study treatment initiation.

Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.


Known allergy to any of the drugs used in the study.

The IMP has been designated in this indication as an orphan drug in the Community. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.

Cancer AND drug name. Committee on Advanced l-asparagiansa CAT has issued a classification for this product.

Trials with results Trials without results. Subjects must have a serum creatinine level that is?

Medicinas para Quimioterapia – Nombres de Medicina

How to search [pdf]. Relapsed or Refractory Acute Lymphoblastic Leukemia. Positive culture efecgos bacteria or fungus within 14 days of the initiation of therapy 7.

Adequate liver function, defined as both of the following: The trial involves single site in the Member State concerned. IMP with orphan designation in the indication.

l-asparaginasa efectos adversos pdf – PDF Files

Active treatment for graft-versus-host disease 6. Clear advanced search filters.

Pneumonia AND sponsor name. Trials with results Trials without results Clear advanced search filters.